PE20050231A1 - Derivados de piperidinium y pirrolidinium como antagonistas del receptor muscarinico m3 - Google Patents

Derivados de piperidinium y pirrolidinium como antagonistas del receptor muscarinico m3

Info

Publication number
PE20050231A1
PE20050231A1 PE2004000611A PE2004000611A PE20050231A1 PE 20050231 A1 PE20050231 A1 PE 20050231A1 PE 2004000611 A PE2004000611 A PE 2004000611A PE 2004000611 A PE2004000611 A PE 2004000611A PE 20050231 A1 PE20050231 A1 PE 20050231A1
Authority
PE
Peru
Prior art keywords
hydroxy
alkyl
piperidinium
diphenyl
methyl
Prior art date
Application number
PE2004000611A
Other languages
English (en)
Inventor
Stephen Paul Collingwood
Urs Baettig
Clive Mccarthy
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33554160&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20050231(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0314697A external-priority patent/GB0314697D0/en
Priority claimed from GB0327526A external-priority patent/GB0327526D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20050231A1 publication Critical patent/PE20050231A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A COMPUESTOS DE FORMULA I EN FORMA DE SAL O ZWITERIONICA DONDE R1 Y R3 SON CADA UNO UN GRUPO CARBOCICLICO C3-C15, GRUPO HETEROCICLICO C5-C12; R2 ES H, HIDROXI, ALQUILO C1-C4; L Y M SON CADA UNO (UN ENLACE Y -CH2-CH2-), (-CH2- Y -CH2-CH2-) O (-CH2-CH2- Y -CH2-) RESPECTIVAMENTE; J ES ALQUILENO C1-C2, O UN ENLACE; R4 ES ALQUILO C1-C4; R5 ES ALQUILO C1-C10, HETEROCICLICO DE 5 A 12 MIEMBROS, ALQUENILO C2-C10 ENTRE OTROS. TAMBIEN REFERIDA A UNA COMPOSICION FARMACEUTICA CON COMPUESTOS ANTERIORES COMO INGREDIENTES ACTIVOS DONDE LOS PREFERIDOS SON: BROMURO(1a,1b) DE CIS Y TRANS-4-(2-HIDROXI-2,2-DIFENIL-ACETOXI)-1-METIL-1-(2-FENOXI-ETIL)-PIPERIDINIO; TRIFLUOROACETATO DE (S)-2-(2-HIDROXI-2,2-DIFENIL-ACETOXIMETIL)-1-METIL-1-OCT-2-INIL-PIRROLIDINIO Y BROMURO DE (1S/R,3R)-3-(2-HIDROXI-2,2-DIFENIL-ACETOXI)-1-METIL-1-(2-FENOXI-ETIL)-PIPERIDINIO; ENTRE OTROS. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE CONDICIONES MEDIADAS POR EL RECEPTOR M3 MUSCARINICO
PE2004000611A 2003-06-24 2004-06-22 Derivados de piperidinium y pirrolidinium como antagonistas del receptor muscarinico m3 PE20050231A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0314697A GB0314697D0 (en) 2003-06-24 2003-06-24 Organic compounds
GB0327526A GB0327526D0 (en) 2003-11-26 2003-11-26 Organic compounds

Publications (1)

Publication Number Publication Date
PE20050231A1 true PE20050231A1 (es) 2005-05-20

Family

ID=33554160

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000611A PE20050231A1 (es) 2003-06-24 2004-06-22 Derivados de piperidinium y pirrolidinium como antagonistas del receptor muscarinico m3

Country Status (15)

Country Link
US (1) US7947730B2 (es)
EP (1) EP1638940B1 (es)
JP (1) JP2008529965A (es)
AR (1) AR044851A1 (es)
AT (1) ATE478845T1 (es)
AU (1) AU2004251867B2 (es)
BR (1) BRPI0411738A (es)
CA (1) CA2526991C (es)
DE (1) DE602004028821D1 (es)
MX (1) MXPA05013823A (es)
PE (1) PE20050231A1 (es)
PL (1) PL1638940T3 (es)
PT (1) PT1638940E (es)
TW (1) TW200526573A (es)
WO (1) WO2005000815A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0410712D0 (en) 2004-05-13 2004-06-16 Novartis Ag Organic compounds
GB0428416D0 (en) 2004-12-24 2005-02-02 Novartis Ag Organic compounds
GB0428418D0 (en) 2004-12-24 2005-02-02 Novartis Ag Organic compounds
AU2006315657B2 (en) 2005-11-10 2011-12-01 Shell Internationale Research Maatschappij B.V. Soft anticholinergic esters
US7417147B2 (en) 2005-11-10 2008-08-26 Bodor Nicholas S Soft anticholinergic zwitterions
WO2007068929A1 (en) * 2005-12-16 2007-06-21 Argenta Discovery Ltd. Cyclic amine derivatives and their uses
JP2009534463A (ja) * 2006-04-24 2009-09-24 アストラゼネカ・アクチエボラーグ 例えば慢性気管支閉塞、喘息および過活動膀胱の処置に有用な、ムスカリンｍ３受容体アンタゴニスト活性を有する環状アミノアルコールの新規アルキルエステル
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
US20100112061A1 (en) * 2006-12-13 2010-05-06 William Baker Monophosphates as Mutual Prodrugs of Muscarinic Receptor Antagonists and Beta-Agonists for the Treatment of COPD And Chronic Bronchitis
CA2675942C (en) * 2007-02-23 2016-04-12 Theravance, Inc. Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists
ATE531692T1 (de) 2007-09-07 2011-11-15 Theravance Inc Als antagonisten am muskarinrezeptor geeignete guanidinhaltige verbindungen
US8017617B2 (en) 2007-12-14 2011-09-13 Theravance, Inc. Amidine-containing compounds useful as muscarinic receptor antagonists
AU2008356409B2 (en) 2008-05-13 2012-01-19 Astrazeneca Ab Quinuclidine derivatives as muscarinic M3 receptor antagonists
EP2426121A4 (en) * 2009-04-30 2012-10-31 Teijin Pharma Ltd QUARTER AMMONIUM SALT CONNECTION
WO2014014698A2 (en) * 2012-07-16 2014-01-23 Barry University Inc. Bitopic muscarinic agonists and antagonists and methods of synthesis and use thereof
PL3111978T3 (pl) 2015-07-03 2022-01-24 Novartis Ag Inhalator przystosowany do odczytu informacji przechowywanych w środkach przechowywania danych pojemnika
WO2021183639A1 (en) * 2020-03-11 2021-09-16 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3240784A (en) * 1966-03-15 Esters of quaternary z-hydroxy methyl piperidinium compounds
US2746966A (en) * 1953-11-02 1956-05-22 Lakeside Lab Inc Esters of bis-(nu-substituted-3-hydroxypiperidinium) alkanes
GB833820A (en) * 1957-10-17 1960-04-27 Beecham Res Lab Improvements in or relating to the preparation of pyrrolidyl esters and quaternary compounds thereof
JPS6018661B2 (ja) * 1976-01-01 1985-05-11 太田製薬株式会社 １−（１，３−ジオキソラン−４−イルメチル）ピペリジノ−ル誘導体
JPS5427570A (en) * 1977-07-30 1979-03-01 Ota Pharma Stereoisomer of 44acyloxyy11 alkyll11*1*33dioxolanee44 ylmethyl* pideridinium salt derivative
JPS5679688A (en) * 1979-12-04 1981-06-30 Ota Seiyaku Kk 4-acyloxy-1- 1,3-dioxoran-2-ylmethyl piperidine derivative and its production
JPS5835177A (ja) * 1981-08-26 1983-03-01 Dainippon Pharmaceut Co Ltd ２−環状アミノ−２−（１，２−ベンズイソキサゾ−ル−３−イル）酢酸エステル類並びにその酸付加塩類および第４級アンモニウム塩類
JPS58208270A (ja) * 1982-05-28 1983-12-03 Dainippon Pharmaceut Co Ltd α−環状アミノフエニル酢酸エステル類並びにその酸付加塩類及び第４級アンモニウム塩類
GB9023023D0 (en) * 1990-10-23 1990-12-05 Barlow Richard B Pharmaceutical compositions
WO1996033973A1 (fr) * 1995-04-28 1996-10-31 Banyu Pharmaceutical Co., Ltd. Derives disubstitues en position 1,4 de piperidine
EP0937041B1 (de) * 1996-11-11 2003-04-23 Christian R. Noe Verwendung eines pharmazeutisch geeigneten Salzes von (3R,2'R)-3-[(Cyclopentyl-hydroxyphenylacetyl)oxy]-1,1-dimethyl-pyrrolidinium zur Herstellung eines Arzneimittels
CA2415468A1 (en) * 2000-07-11 2003-01-10 Yoshio Ogino Ester derivatives
ES2206021B1 (es) * 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
US7417147B2 (en) * 2005-11-10 2008-08-26 Bodor Nicholas S Soft anticholinergic zwitterions

Also Published As

Publication number Publication date
WO2005000815A3 (en) 2005-04-14
MXPA05013823A (es) 2006-02-28
EP1638940B1 (en) 2010-08-25
DE602004028821D1 (de) 2010-10-07
ATE478845T1 (de) 2010-09-15
US20060287362A1 (en) 2006-12-21
PT1638940E (pt) 2010-11-08
PL1638940T3 (pl) 2011-02-28
BRPI0411738A (pt) 2006-08-08
AU2004251867A1 (en) 2005-01-06
AR044851A1 (es) 2005-10-05
WO2005000815A2 (en) 2005-01-06
EP1638940A2 (en) 2006-03-29
CA2526991C (en) 2012-03-27
US7947730B2 (en) 2011-05-24
AU2004251867B2 (en) 2008-08-07
JP2008529965A (ja) 2008-08-07
CA2526991A1 (en) 2005-01-06
TW200526573A (en) 2005-08-16

Similar Documents

Publication Publication Date Title
PE20050231A1 (es) Derivados de piperidinium y pirrolidinium como antagonistas del receptor muscarinico m3
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
PE20050874A1 (es) Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
AR046711A1 (es) 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones
PE20061316A1 (es) Derivados de pirazol como antagonistas del receptor de progesterona
CO5680412A2 (es) Agonistas del receptor adrenergico etilamino beta 2 sustituido con amino
PE20090772A1 (es) Derivados de bencimidazol
PE20070217A1 (es) Derivados de isoquinolona sustituidos con piperidinilo
PE20091884A1 (es) Antagonistas de cgrp seleccionados, procedimiento para su preparacion, asi como su uso como medicamento
PE20060383A1 (es) Nuevos derivados amino de urea ciclicos como inhibidores de quinasa
PE20060691A1 (es) Serinamidas sustituidas por benzoilo
PE20071100A1 (es) Derivados de azepinoindol como agentes farmaceuticos
CR9459A (es) Derivados benzodioxano y benzodioxolano y usos de los mismos
PE20070115A1 (es) Derivados de [1,3,5]-triazina como inhibidores de aspartil proteasas
PE20071023A1 (es) Azaciclilaminas-n-sustituidas como antagonistas de histamina-3
PE20080839A1 (es) Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
ECSP003828A (es) Antagonistas de neurokinina selectivos
PE20071245A1 (es) COMPUESTOS INDOL SULFONAMIDA COMO MODULADORES DEL RECEPTOR DE PROGESTERONA SELECTIVOS (SPRMs)
PE20090620A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
PE20110671A1 (es) Derivados de diazabicicloalcanos como moduladores de la actividad de los receptores nicotinicos de la acetilcolina
PE20050999A1 (es) Cetoamidas novedosas con p4 ciclicos como inhibidores de ns3 serina proteasa del virus de hepatitis c
PE20070491A1 (es) Compuestos derivados de 9-azabiciclo[3.3.1]nonano como inhibidores de la recaptacion de neurotransmisores de monoamina
PE20090648A1 (es) Compuestos para el tratamiento de la hepatitis c
PE20060977A1 (es) Derivados de piperidinilo como bloqueantes de canales de calcio

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed